Intest Res.  2017 Jan;15(1):90-96. 10.5217/ir.2017.15.1.90.

Maternal and fetal outcomes in pregnant Japanese women with inflammatory bowel disease: our experience with a series of 23 cases

• Minami N
• Matsuura M
• Koshikawa
• Yamada S
• Honzawa Y
• Yamamoto S
• Nakase H

• KMID: 2368490
• DOI: http://doi.org/10.5217/ir.2017.15.1.90

Abstract

BACKGROUND/AIMS
Our physicians work to expand the possibilities to treat female patients with inflammatory bowel disease (IBD) who wish to become pregnant. Although many drugs, including 5-aminosalicylate (5-ASA), corticosteroids, immunomodulators, and biologics, are used safely during pregnancy, few reports have described the therapeutic regimen throughout pregnancy and the management of patients who relapse during pregnancy precisely. The aim of this study was to assess the management of patients with IBD during pregnancy.
METHODS
We identified 19 patients (five with Crohn's disease and 14 with ulcerative colitis [UC]) who became pregnant with a total of 23 pregnancies between May 2005 and May 2015 by reviewing the medical records of Kyoto University Hospital. The following data were collected: the maternal variables, the IBD treatment type, the disease activity, the pregnancy outcome, and the mode of delivery.
RESULTS
Among the 19 patients, 18 had become pregnant after being diagnosed with IBD, while one had developed UC newly after pregnancy. Throughout the gestation, all patients were treated with probiotics, 5-ASA, prednisolone, cytapheresis, or infliximab. The relapse rate during pregnancy was 21.7% (5/23 cases). The five patients who experienced a relapse were able to pursue their pregnancy after intensification of their treatments. There were no adverse fetal or neonatal problems, except in one case that required an emergency Caesarean section because of placental dysfunction and in which a very low-birth-weight infant was born preterm.
CONCLUSIONS
Our present data confirmed that even if the disease flares up during pregnancy, good pregnancy outcomes can be achieved with an optimal intensification of the patient's treatment.

Keyword

Inflammatory bowel disease; Pregnancy; Therapeutic management

MeSH Terms

Adrenal Cortex Hormones
Asian Continental Ancestry Group*
Biological Products
Cesarean Section
Colitis, Ulcerative
Crohn Disease
Cytapheresis
Emergencies
Female
Humans
Immunologic Factors
Infant, Low Birth Weight
Infant, Newborn
Inflammatory Bowel Diseases*
Infliximab
Medical Records
Mesalamine
Prednisolone
Pregnancy
Pregnancy Outcome
Probiotics
Recurrence
Adrenal Cortex Hormones
Biological Products
Immunologic Factors
Infliximab
Mesalamine
Prednisolone

Reference

1. Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med. 2009; 361:2066–2078. PMID: 19923578.

2. Loftus EV Jr, Sandborn WJ. Epidemiology of inflammatory bowel disease. Gastroenterol Clin North Am. 2002; 31:1–20. PMID: 12122726.

3. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 2007; 369:1641–1657. PMID: 17499606.

4. van der Woude CJ, Ardizzone S, Bengtson MB, et al. The second European evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease. J Crohns Colitis. 2015; 9:107–124. PMID: 25602023.

5. Walmsley RS, Ayres RC, Pounder RE, Allan RN. A simple clinical colitis activity index. Gut. 1998; 43:29–32. PMID: 9771402.

6. Harvey RF, Bradshaw JM. A simple index of Crohn’s-disease activity. Lancet. 1980; 1:514. PMID: 6102236.

7. Bortoli A, Pedersen N, Duricova D, et al. Pregnancy outcome in inflammatory bowel disease: prospective European case-control ECCO-EpiCom study, 2003-2006. Aliment Pharmacol Ther. 2011; 34:724–734. PMID: 21815900.

8. Vermeire S, Carbonnel F, Coulie PG, et al. Management of inflammatory bowel disease in pregnancy. J Crohns Colitis. 2012; 6:811–823. PMID: 22595185.

9. Kane SV, Acquah LA. Placental transport of immunoglobulins: a clinical review for gastroenterologists who prescribe therapeutic monoclonal antibodies to women during conception and pregnancy. Am J Gastroenterol. 2009; 104:228–233. PMID: 19098873.

10. Vasiliauskas EA, Church JA, Silverman N, Barry M, Targan SR, Dubinsky MC. Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn. Clin Gastroenterol Hepatol. 2006; 4:1255–1258. PMID: 17045211.

11. Zelinkova Z, van der Ent C, Bruin KF, et al. Effects of discontinuing anti-tumor necrosis factor therapy during pregnancy on the course of inflammatory bowel disease and neonatal exposure. Clin Gastroenterol Hepatol. 2013; 11:318–321. PMID: 23103819.

12. Komoto S, Motoya S, Nishiwaki Y, et al. Pregnancy outcome in women with inflammatory bowel disease treated with anti-tumor necrosis factor and/or thiopurine therapy: a multicenter study from Japan. Intest Res. 2016; 14:139–145. PMID: 27175114.

13. Sawada K, Ohnishi K, Fukui S, et al. Leukocytapheresis therapy, performed with leukocyte removal filter, for inflammatory bowel disease. J Gastroenterol. 1995; 30:322–329. PMID: 7647899.

14. Okada H, Makidono C, Takenaka R, et al. Therapeutic efficacy of leukocytapheresis in a pregnant woman with severe active ulcerative colitis. Digestion. 2006; 74:15–18. PMID: 16940730.

15. Takahashi H, Sugawara K, Sugimura M, et al. Flare up of ulcerative colitis during pregnancy treated by adsorptive granulocyte and monocyte apheresis: therapeutic outcomes in three pregnant patients. Arch Gynecol Obstet. 2013; 288:341–347. PMID: 23404436.

16. Riis L, Vind I, Politi P, et al. Does pregnancy change the disease course? A study in a European cohort of patients with inflammatory bowel disease. Am J Gastroenterol. 2006; 101:1539–1545. PMID: 16863558.

17. Coelho J, Beaugerie L, Colombel JF, et al. Pregnancy outcome in patients with inflammatory bowel disease treated with thiopurines: cohort from the CESAME study. Gut. 2011; 60:198–203. PMID: 21115547.

18. Jharap B, de Boer NK, Stokkers P, et al. Intrauterine exposure and pharmacology of conventional thiopurine therapy in pregnant patients with inflammatory bowel disease. Gut. 2014; 63:451–457. PMID: 23424097.

19. Hawthorne AB, Logan RF, Hawkey CJ, et al. Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. BMJ. 1992; 305:20–22. PMID: 1638191.

20. Kennedy NA, Kalla R, Warner B, et al. Thiopurine withdrawal during sustained clinical remission in inflammatory bowel disease: relapse and recapture rates, with predictive factors in 237 patients. Aliment Pharmacol Ther. 2014; 40:1313–1323. PMID: 25284134.

21. Moreno-Rincón E, Benítez JM, Serrano-Ruiz FJ, et al. Prognosis of patients with ulcerative colitis in sustained remission after thiopurines withdrawal. Inflamm Bowel Dis. 2015; 21:1564–1571. PMID: 26070002.